Crystal structure of the human σ1 receptor

Nature

Volumn 532, Issue 7600, 2016, Pages 527-530

  Schmidt, Hayden R ^a   Zheng, Sanduo ^a   Gurpinar, Esin ^a   Koehl, Antoine ^b   Manglik, Aashish ^b   Kruse, Andrew C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; CLEMASTINE; DEXTROMETHORPHAN; FLUOXETINE; GLUTAMIC ACID; GLUTAMINE; HALOPERIDOL; HISTIDINE DERIVATIVE; ISOLEUCINE; LEUCINE; METHIONINE DERIVATIVE; OLIGOMER; PHENYLALANINE DERIVATIVE; QUETIAPINE; SIGMA 1 OPIATE RECEPTOR; TRYPTOPHAN DERIVATIVE; VALINE; 1-PROPYL-5-(3-P-TOLYLISOXAZOL-5-YL)-1,2,3,6-TETRAHYDROPYRIDINE; BENZAMIDE DERIVATIVE; ISOXAZOLE DERIVATIVE; LIGAND; N-(N-BENZYLPIPERIDIN-4-YL)-4-IODOBENZAMIDE; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; SIGMA OPIATE RECEPTOR; SIGMA-1 RECEPTOR;

CELLS AND CELL COMPONENTS; CHEMICAL BINDING; CRYSTAL STRUCTURE; DISEASE; DRUG; GENETICS; LIGAND; MOLECULAR ANALYSIS; NERVOUS SYSTEM DISORDER; PHYSIOLOGY; PROTEIN; RECOGNITION; RODENT; TIME DOMAIN REFLECTOMETRY;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CELL SURFACE; CHEMICAL STRUCTURE; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENDOPLASMIC RETICULUM MEMBRANE; ENZYME ACTIVE SITE; GENE MUTATION; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; LIGAND BINDING; MOLECULAR WEIGHT; NONHUMAN; OLIGOMERIZATION; PHENOTYPE; PLASTICITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN STRUCTURE; SF9 CELL LINE; CHEMICAL PHENOMENA; CHEMISTRY; ENDOPLASMIC RETICULUM; ENZYME SPECIFICITY; INTRACELLULAR MEMBRANE; METABOLISM; PROTEIN TERTIARY STRUCTURE; X RAY CRYSTALLOGRAPHY;

BENZAMIDES; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; ENDOPLASMIC RETICULUM; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INTRACELLULAR MEMBRANES; ISOXAZOLES; LIGANDS; MODELS, MOLECULAR; PIPERIDINES; PROTEIN STRUCTURE, TERTIARY; PYRIDINES; RECEPTORS, SIGMA; SUBSTRATE SPECIFICITY;

EID: 84964809019     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature17391     Document Type: Article

References (30)

1. Cobos, E. J., Entrena, J. M., Nieto, F. R., Cendán, C. M. & Del Pozo, E. Pharmacology and therapeutic potential of sigma1 receptor ligands. Curr. Neuropharmacol. 6, 344-366 (2008).
2. Mavlyutov, T. A., Guo, L. W., Epstein, M. L. & Ruoho, A. E. Role of the sigma-1 receptor in amyotrophic lateral sclerosis (ALS). J. Pharmacol. Sci. 127, 10-16 (2015).
3. Brownstein, M. J. A brief history of opiates, opioid peptides, and opioid receptors. Proc. Natl Acad. Sci. USA 90, 5391-5393 (1993).
4. Largent, B. L., Wikström, H., Gundlach, A. L. & Snyder, S. H. Structural determinants of sigma receptor affinity. Mol. Pharmacol. 32, 772-784 (1987).
5. Hanner, M. et al. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc. Natl Acad. Sci. USA 93, 8072-8077 (1996).
6. Su, T. P., Hayashi, T., Maurice, T., Buch, S. & Ruoho, A. E. The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol. Sci. 31, 557-566 (2010).
7. Al-Saif, A., Al-Mohanna, F. & Bohlega, S. A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Ann. Neurol. 70, 913-919 (2011).
8. Mavlyutov, T. A. et al. Lack of sigma-1 receptor exacerbates ALS progression in mice. Neuroscience 240, 129-134 (2013).
9. Hayashi, T. & Su, T. P. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. Cell 131, 596-610 (2007).
10. Wu, Z. & Bowen, W. D. Role of sigma-1 receptor C-terminal segment in inositol 1,4,5-trisphosphate receptor activation: constitutive enhancement of calcium signaling in MCF-7 tumor cells. J. Biol. Chem. 283, 28198-28215 (2008).
11. Kim, F. J. et al. ?1 Receptor modulation of G-protein-coupled receptor signaling: potentiation of opioid transduction independent from receptor binding. Mol. Pharmacol. 77, 695-703 (2010).
12. Dussossoy, D. et al. Colocalization of sterol isomerase and sigma1 receptor at endoplasmic reticulum and nuclear envelope level. Eur. J. Biochem. 263, 377-386 (1999).
13. Aydar, E., Palmer, C. P., Klyachko, V. A. & Jackson, M. B. The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron 34, 399-410 (2002).
14. Akunne, H. C. et al. The pharmacology of the novel and selective sigma ligand, PD 144418. Neuropharmacology 36, 51-62 (1997).
15. Lever, J. R. et al. Relationship between cerebral sigma-1 receptor occupancy and attenuation of cocaine's motor stimulatory effects in mice by PD144418. J. Pharmacol. Exp. Ther. 351, 153-163 (2014).
16. John, C. S., Vilner, B. J. & Bowen, W. D. Synthesis and characterization of [125I]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide, a new ? receptor radiopharmaceutical: high-Affinity binding to MCF-7 breast tumor cells. J. Med. Chem. 37, 1737-1739 (1994).
17. Bermack, J. E. & Debonnel, G. Distinct modulatory roles of sigma receptor subtypes on glutamatergic responses in the dorsal hippocampus. Synapse 55, 37-44 (2005).
18. Tagashira, H., Shinoda, Y., Shioda, N. & Fukunaga, K. Methyl pyruvate rescues mitochondrial damage caused by SIGMAR1 mutation related to amyotrophic lateral sclerosis. Biochim. Biophys. Acta 1840, 3320-3334 (2014).
19. Shin, E. J. et al. Dextromethorphan attenuates trimethyltin-induced neurotoxicity via ?1 receptor activation in rats. Neurochem. Int. 50, 791-799 (2007).
20. Roth, B. L., Lopez, E., Patel, S. & Kroeze, W. K. The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches? Neuroscientist 6, 252-262 (2000).
21. Seth, P. et al. Expression pattern of the type 1 sigma receptor in the brain and identity of critical anionic amino acid residues in the ligand-binding domain of the receptor. Biochim. Biophys. Acta 1540, 59-67 (2001).
22. Yamamoto, H. et al. Amino acid residues in the transmembrane domain of the type 1 sigma receptor critical for ligand binding. FEBS Lett. 445, 19-22 (1999).
23. Kovács, K. J. & Larson, A. A. Up-regulation of [3H]DTG but not [3H] (+)-pentazocine labeled sigma sites in mouse spinal cord by chronic morphine treatment. Eur. J. Pharmacol. 350, 47-52 (1998).
24. Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E. & Gilbert, P. E. The effects of morphine-And nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197, 517-532 (1976).
25. Nguyen, L. et al. Role of sigma-1 receptors in neurodegenerative diseases. J. Pharmacol. Sci. 127, 17-29 (2015).
26. Mei, J. & Pasternak, G. W. ?1 Receptor modulation of opioid analgesia in the mouse. J. Pharmacol. Exp. Ther. 300, 1070-1074 (2002).
27. Maurice, T. & Su, T. P. The pharmacology of sigma-1 receptors. Pharmacol. Ther. 124, 195-206 (2009).
28. Gromek, K. A. et al. The oligomeric states of the purified sigma-1 receptor are stabilized by ligands. J. Biol. Chem. 289, 20333-20344 (2014).
29. Mishra, A. K. et al. The sigma-1 receptors are present in monomeric and oligomeric forms in living cells in the presence and absence of ligands. Biochem. J. 466, 263-271 (2015).
30. Lomize, M. A., Pogozheva, I. D., Joo, H., Mosberg, H. I. & Lomize, A. L. OPM database and PPM web server: resources for positioning of proteins in membranes. Nucleic Acids Res. 40, D370-D376 (2012).